Get the Stockscreener App
21.33
2.80%
0.58
Arrowhead Pharmaceuticals Inc stock is traded at $21.33, with a volume of 2.51M.
It is up +2.80% in the last 24 hours and up +42.58% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$20.75
Open:
$20.92
24h Volume:
2.51M
Relative Volume:
1.33
Market Cap:
$2.95B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-15.35
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
+4.00%
1M Performance:
+42.58%
6M Performance:
+7.19%
1Y Performance:
-12.47%
1-Day Range:
$20.72
$21.70
1-Week Range:
$19.42
$21.70
52-Week Range:
$9.57
$27.34
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
21.33 | 2.75B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Arrowhead Pharmaceuticals Inc. stock momentum explainedJuly 2025 Setups & Detailed Earnings Play Alerts - Newser
Why Arrowhead Pharmaceuticals Inc. stock attracts strong analyst attentionWeekly Volume Report & Short-Term High Return Strategies - Newser
Arrowhead Pharmaceuticals Inc. stock daily chart insightsMarket Risk Analysis & Consistent Profit Trading Strategies - Newser
How to forecast Arrowhead Pharmaceuticals Inc. trends using time series2025 Market WrapUp & Precise Buy Zone Identification - Newser
Published on: 2025-08-19 14:07:49 - Newser
Published on: 2025-08-19 13:49:27 - Newser
Arrowhead Pharmaceuticals Inc. stock outlook for YEAROptions Play & Verified Swing Trading Watchlist - Newser
Using AI based signals to follow Arrowhead Pharmaceuticals Inc.2025 Institutional Moves & Community Consensus Picks - Newser
How to use a screener to detect Arrowhead Pharmaceuticals Inc. breakoutsJuly 2025 Opening Moves & Risk Controlled Swing Trade Alerts - Newser
Published on: 2025-08-19 05:37:04 - Newser
Deutsche Bank AG Trims Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - Defense World
Order flow analysis tools used on Arrowhead Pharmaceuticals Inc.Day Trade & Breakout Confirmation Trade Signals - Newser
How Arrowhead Pharmaceuticals Inc. stock performs during market volatilityJuly 2025 Decliners & Smart Investment Allocation Insights - Newser
Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue - MSN
Arrowhead Pharmaceuticals Sees 24.9% Surge Amid $100 Million Licensing Deal with Sarepta Therapeutics - AInvest
FY2025 Earnings Estimate for ARWR Issued By Leerink Partnrs - Defense World
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives - MSN
News impact scoring models applied to Arrowhead Pharmaceuticals Inc.2025 Biggest Moves & AI Powered Market Entry Strategies - Newser
Institutional scanner results for Arrowhead Pharmaceuticals Inc.July 2025 Market Mood & Breakout Confirmation Alerts - Newser
Analyzing recovery setups for Arrowhead Pharmaceuticals Inc. investorsGDP Growth & Weekly High Return Forecasts - Newser
10 Double-Digit Winners You Wish You Bought Yesterday - Insider Monkey
What is HC Wainwright’s Forecast for ARWR FY2025 Earnings? - Defense World
Key External Factors That Drive Arrowhead Pharmaceuticals Inc. Stock Price MovementsJuly 2025 Trade Ideas & Smart Money Movement Alerts - Newser
Insider Sell: James Hamilton Sells 10,000 Shares of Arrowhead Ph - GuruFocus
Leerink Partners Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $21 - 富途牛牛
XTX Topco Ltd Purchases New Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals shares rise 7.99% intraday after Sarepta Therapeutics sold 9.27 million shares in a block trade. - AInvest
Arrowhead Pharmaceuticals shares rise 8.63% intraday after Sarepta Therapeutics sold 9.27 million shares in a block trade. - AInvest
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Sarepta Sells Arrowhead Shares, Activates $100M Milestone Payment - AInvest
Arrowhead Pharmaceuticals Redeems $50M Stock, Receives $50M Cash from Sarepta Therapeutics - AInvest
Sarepta's Strategic Investment in Arrowhead Ends in Loss: Analyst Cites Credibility Concerns - AInvest
Sarepta Therapeutics Advances siRNA Collaboration and Sells Arrowhead Stock - AInvest
Arrowhead Pharmaceuticals Redeems $50M of Common Stock from Sarepta Therapeutics - AInvest
Equities Analysts Offer Predictions for ARWR FY2025 Earnings - Defense World
Momentum divergence signals in Arrowhead Pharmaceuticals Inc. chartOil Prices & Target Return Focused Stock Picks - Newser
Sarepta Sells Arrowhead Shares To Raise Cash, Pay Arrowhead - insights.citeline.com
Arrowhead Pharmaceuticals Shares Drop After Sarepta Sells Stake - MSN
Arrowhead Pharmaceuticals Inc. Attempts Reversal From Key Support2025 Winners & Losers & Risk Managed Investment Entry Signals - sundaytimes.kr
Arrowhead Pharmaceuticals Advances Plozasiran Study for Hypertriglyceridemia - TipRanks
Sarepta Sells Arrowhead Stake to Fund Milestone Payment - TradingView
Arrowhead Pharmaceuticals stock falls after Sarepta sells shares - Investing.com
Arrowhead Pharmaceuticals stock falls after Sarepta sells shares By Investing.com - Investing.com Nigeria
Is Arrowhead Pharmaceuticals Inc. Forming a Consolidation BaseJuly 2025 Macro Moves & Risk Controlled Stock Pick Alerts - classian.co.kr
New Product Launches: Will They Boost Arrowhead Pharmaceuticals Inc. Stock in 2025Market Growth Review & Low Drawdown Investment Ideas - Newser
Sarepta Therapeutics shares rise 2.94% premarket after selling $174 million Arrowhead stock. - AInvest
Sarepta offloads Arrowhead stake to fund milestone payment - The Pharma Letter
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics - BioSpace
Sarepta Sells Arrowhead Stock, Activates $100M Milestone Payment - AInvest
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics - MSN
Arrowhead redeems $50M of common stock - TipRanks
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arrowhead Pharmaceuticals Inc Stock (ARWR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hamilton James C | Chief Medical Officer |
Aug 13 '25 |
Sale |
20.00 |
611 |
12,220 |
271,511 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):